Telix ADRs Fall After Company Discloses SEC Subpoena

Dow Jones

2025/07/24

By Dean Seal

Telix Pharmaceuticals' American depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission.

The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date.

The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates.

Telix said it is fully cooperating with the SEC and in the process of responding to its request.

"At this stage, this matter is a fact-finding request," the company said.

The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates.

Write to Dean at dean.seal@wsj.com

(END) Dow Jones Newswires

July 23, 2025 12:55 ET (16:55 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2553244422"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553244422\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553244422?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-24 00:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553244422","market":"fut","top_or_hot":-1,"title":"Telix ADRs Fall After Company Discloses SEC Subpoena","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a>' <a href=\"https://laohu8.com/S/AFG\">American</a> depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission. \n</p>\n<p>\n  The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date. \n</p>\n<p>\n  The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates. \n</p>\n<p>\n  Telix said it is fully cooperating with the SEC and in the process of responding to its request. \n</p>\n<p>\n  \"At this stage, this matter is a fact-finding request,\" the company said. \n</p>\n<p>\n  The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2025 12:55 ET (16:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix ADRs Fall After Company Discloses SEC Subpoena</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix ADRs Fall After Company Discloses SEC Subpoena\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-07-24 00:55</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a>' <a href=\"https://laohu8.com/S/AFG\">American</a> depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission. \n</p>\n<p>\n  The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date. \n</p>\n<p>\n  The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates. \n</p>\n<p>\n  Telix said it is fully cooperating with the SEC and in the process of responding to its request. \n</p>\n<p>\n  \"At this stage, this matter is a fact-finding request,\" the company said. \n</p>\n<p>\n  The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2025 12:55 ET (16:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2553244422","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553244422","pubTimestamp":1753289700,"columns":[{"name":"政策監管","id":32,"label_key":"policyRegulatory"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Telix Pharmaceuticals' American depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission.The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date.The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates.Telix said it is fully cooperating with the SEC and in the process of responding to its request.\"At this stage, this matter is a fact-finding request,\" the company said.The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"Telix ADR在公司披露SEC传票后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":0.9},"content_text":"By Dean Seal \n\n\n \n\n\nTelix Pharmaceuticals' American depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission. \n\n\n  The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date. \n\n\n  The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates. \n\n\n  Telix said it is fully cooperating with the SEC and in the process of responding to its request. \n\n\n  \"At this stage, this matter is a fact-finding request,\" the company said. \n\n\n  The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates. \n\n\n \n\n\n  Write to Dean at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 23, 2025 12:55 ET (16:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}